Noveris Health Sciences Inc.
MYCOF
$2.00
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 355.60K | 386.90K | 849.50K | 1.26M | 1.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 326.40K | 357.70K | -1.08M | 198.70K | 1.67M |
| Operating Income | -326.40K | -357.70K | 1.08M | -198.70K | -1.67M |
| Income Before Tax | 1.15M | 2.10M | 1.62M | 109.10K | -1.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.15 | 2.10 | 1.62 | 0.11 | -1.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.15M | 2.10M | 1.62M | 109.10K | -1.83M |
| EBIT | -326.40K | -357.70K | 1.08M | -198.70K | -1.67M |
| EBITDA | -- | -- | 1.44M | 239.30K | -1.41M |
| EPS Basic | 1.80 | 1.70 | 1.32 | 0.09 | -1.50 |
| Normalized Basic EPS | -0.21 | -0.34 | 0.35 | -0.41 | -1.36 |
| EPS Diluted | 1.80 | 1.70 | 1.32 | 0.09 | -1.50 |
| Normalized Diluted EPS | -0.21 | -0.34 | 0.35 | -0.41 | -1.36 |
| Average Basic Shares Outstanding | 19.58M | 4.94M | 4.94M | 4.94M | 4.93M |
| Average Diluted Shares Outstanding | 19.58M | 4.94M | 4.94M | 4.94M | 4.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |